Immunological requirements for a subunit vaccine against tuberculosis

Immunology and Cell Biology

Volumn 75, Issue 6, 1997, Pages 595-603

  Elhay, Martin J ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Adjuvants; Baciile Calmette Guerin vaccine; Tuberculosis

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INACTIVATED VACCINE; INTERLEUKIN 12; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MURAMYL DIPEPTIDE; PHOSPHORYL LIPID A; QUIL A; TUMOR NECROSIS FACTOR ALPHA;

BCG VACCINATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; INTERFERON PRODUCTION; INTRAVENOUS DRUG ADMINISTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; TUBERCULOSIS; VACCINE PRODUCTION;

MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

EID: 0031417666     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1997.94     Document Type: Conference Paper

References (83)

1. Smith DW. Protective effect of BCG in experimental tuberculosis. Adv. Tuberc. Res. 1985; 22: 1-97.
2. Fine PE. The BCG story: Lessons from the past and implications for the future. Rev. Infect. Dis. 1989; 11(Suppl 2): S353-9.
3. Fine PE. Variation in protection by BCG: Implications of and for heterologous immunity. Lancet 1995; 346: 1339-45.
4. Ponninghaus JM, Fine PE, Sterne JA et al. Efficacy of BCG vaccines against leprosy and tuberculosis in northern Malawi. Lancet 1992; 339: 636-9.
5. ten-Dam HG. Research on BCG vaccination. Adv. Tuberc. Res. 1984; 21: 79-106.
6. Paramasivan CN, Govindan D, Prabhakar R. Somasundaram PR, Subbammal S, Tripathy SP. Species level identification of non-tuberculous mycobacteria from South Indian BCG trial area during 1981. Tubercle 1985; 66: 9-15.
7. Kamala T, Paramasivan CN, Herbert D, Venkatesan P, Prabhakar R. Isolation and identification of environmental mycobacteria in the Mycobacterium bovis BCG trial area of south India. Appl. Environ. Micriobiol. 1994; 60: 2180-3.
8. Herbert D, Paramasivan CN, Prabhakar R. Protective response in guinea pigs exposed to Mycobacterium avium-intracellulare/M. scrofulaceum, BCG & south Indian isolates of M. tuberculosis. Indian J. Med. Res 1994; 99: 1-7.
9. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am. Rev. Respir. Dis. 1966; 94: 553-68.
10. Stanford JL, Shield MJ, Rook GA. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 1981; 62: 55-62.
11. Reynes J, Perez C, Lamaury I, Janbon F, Bertrand A. Bacille Calmette-Guerin adenitis 30 years after immunization in a patient with AIDS. J. Infect. Dis. 1989; 160: 727.
12. Leroy V, Salmi LR, Dupon M et al. Progression of human immunodeficiency virus infection in patients with tuberculosis disease. Am. J. Epidemiol. 1997; 145: 293-300.
13. Goletti D, Weissman D, Jackson RW et al. Effect of Mycobacterium tuberculosis on HIV replication: Role of immune activation. J. Immunol. 1996; 157: 1271-8.
14. Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K, Ellner JJ. Human immune response to Mycobacterium tuberculosis antigens. Infect. Immun. 1991; 59: 665-70.
15. Daugelat S, Guile H, Schoel B, Kaufmann SH. Secreted antigens of Mycobacterium tuberculosis: Characterization with T lymphocytes from patients and contacts after two-dimensional separation. J. Infect. Dis. 1992; 166: 186-90.
16. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 1993; 178: 2249-54.
17. Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J. Infect. Dis. 1993; 167: 1481-97.
18. Andersen P, Andersen ÅB, Srønsen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J. Immunol. 1995; 154: 3359-72.
19. Flesch IE, Kaufmann SH. Activation of tuberculostatic macrophage functions by gamma interferon, interleukin-4, and tumor necrosis factor. Infect. Immun. 1990; 58: 2675-7.
20. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 1993; 178: 2243-7.
21. Cooper AM, Magram J, Ferrante J, Orme I. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 1997; 186: 39-45.
22. Fulton SA, Johnsen JM, Wolf SF, Sieburth DS, Boom WH. Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: Role of phagocytosis. Infect. Immun. 1996; 64: 2523-31.
23. Ladel CH, Szalay G, Riedel D, Kaufmann SH. Interleukin-12 secretion by Mycobacterium tuberculosis-infected macrophages. Infect. Immun. 1997; 65: 1936-8.
24. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 1992; 89: 12 013-17.
25. Orme IM, Miller ES, Roberts AD et al. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection: Evidence for different kinetics and recognition of a wide spectrum of protein antigens. J. Immunol. 1992; 148: 189-96.
26. Laochumroonvorapong P, Wang J, Liu CC et al. Perform, a cytotoxic molecule which mediates cell necrosis is not required for the early control of mycobacterial infection in mice. Infect. Immun. 1997; 65: 127-32.
27. Cooper AM, D'Souza C, Frank AA, Orme IM. The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perform- or granzyme-mediated cytolytic mechanisms. Infect. Immun. 1997; 65: 1317-20.
28. Kumararatne DS, Pithie AS, Drysdale P et al. Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis. Clin. Exp. Immunol. 1990; 80: 314-23.
29. Ravn P, Boesen H, Pedersen BK, Andersen P. Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guérin. J. Immunol. 1997; 158: 1949-55.
30. + T lymphocytes specific for Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 1997; (in press).
31. Mazzaccaro RJ, Gedde M, Jensen ER et al. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 1996; 93: 11 786-91.
32. Xu S, Cooper A, Sturgill-Koszycki S et al. Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected macrophages. J. Immunol. 1994; 153: 2568-78.
33. Denis O, Lozes E, Huygen K. Induction of cytotoxic T-cell responses against culture filtrate antigens in Mycobacterium bovis bacillus Calmette-Guérin-infected mice. Infect. Immun. 1997; 65: 676-84.
34. Cooper AM, Flynn JL. The protective immune response to Mycobacterium tuberculosis. Curr. Opin. Immunol. 1995; 7: 512-16.
35. Kaufmann SHE, Andersen P. Immunity to mycobacteria with emphasis on tuberculosis: Implications for rational design of an effective tuberculosis vaccine. Chem. Immunol. 1997; (in press).
36. Mackaness GB. The relationship of delayed hypersensitivity to acquired cellular resistance. Br. Med. Bull. 1967; 23: 52-4.
37. Collins FM, Kubica GP, Wayne LG. Protection against mycobacterial disease by means of live vaccines tested in experimental animals. In: The Mycobacterial Sourcebook. New York: Marcel Dekker, Inc., 1984; 787-840.
38. Orme IM. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect. Immun. 1988; 56: 3310-12.
39. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 1994; 62: 2536-44.
40. Sørensen AL, Nagai S, Houen G, Andersen P, Andersen ÅB. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 1995; 63: 1710-17.
41. Hubbard RD, Flory CM, Collins FM. Immunization of mice with mycobacterial culture filtrate proteins. Clin. Exp. Immunol. 1992; 87: 94-8
42. Roberts AD, Sonnenberg MG, Ordway DJ et al. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology. 1995; 85: 502-8.
43. Pal PG, Horwitz MA. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immun. 1992; 60: 4781-92.
44. Horwitz MA, Lee BW, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 1995; 92: 1530-4.
45. Andersen P, Askgaard D, Ljungqvist L, Bennedsen J, Heron I. Proteins released from Mycobacterium tuberculosis during growth. Infect. Immun. 1991; 59: 1905-10.
46. Andersen P, Askgaard D, Gottschau A, Bennedsen J, Nagai S, Heron I. Identification of immunodominant antigens during infection with Mycobacterium tuberculosis. Scand. J. Immunol. 1992; 36: 823-31.
47. Brandt L, Oettinger T, Holm A, Andersen P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J. Immunol. 1996; 157: 3527-33.
48. Boesen H, Jensen BN, Wilcke T, Andersen P. Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect. Immun. 1995; 63: 1491-7.
49. Pollock JM, Andersen P. Predominant recognition of the ESAT-6 protein in the first phase of infection with Mycobacterium bovis in cattle. Infect. Immun. 1997; 65: 2587-92.
50. Lee BY, Horwitz MA. Identification of macrophage and stress-induced proteins of Mycobacterium tuberculosis. J. Clin. Invest. 1995; 96: 245-9.
51. Alavi MR, Affronti LF. Induction of mycobacterial proteins during phagocytosis and heat shock: A time interval analysis. J. Leukoc. Biol. 1994; 55: 633-41.
52. Andersen ÅB, Ljungqvist L, Hasløv K, Bentzon MW. MPB 64 possesses 'tuberculosis-complex'-specific B- and T-cell epitopes. Scand. J. Immunol. 1991; 34: 365-72.
53. Li H, Ulstrup JC, Jonassen TO, Melby K, Nagai S, Harboe M. Evidence for absence of the MPB64 gene in some substrains of Mycobacterium bovis BCG. Infect. Immun. 1993; 61: 1730-4.
54. Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect. Immun. 1996; 64: 16-22.
55. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 1996; 178: 1274-82.
56. Wiker HG, Harboe M. The antigen 85 complex: A major secretion product of Mycobacterium tuberculosis. Microbiol. Rev. 1992; 56: 648-61.
57. Godfrey HP, Feng Z, Mandy S et al. Modulation of expression of delayed hypersensitivity by mycobacterial antigen 85 fibronectin-binding proteins. Infect. Immun. 1992; 60: 2522-8.
58. Andersen P. The T cell response to secreted antigens of Mycobacterium tuberculosis. Immunobiology 1994; 191: 537-17.
59. Launois P, DeLeys R, Niang MN et al. T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect. Immun. 1994; 62: 3679-87.
60. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997; 276: 1420-2.
61. Huygen K, Content J, Denis O et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 1996; 2: 893-8.
62. Wiegeshaus E, Balasubramanian V, Smith DW. Immunity to tuberculosis from the perspective of pathogenesis. Infect. Immun. 1989; 57: 3671-6.
63. Silva CL, Pietro RL, Januario A et al. Protection against tuberculosis by bone marrow cells expressing mycobacterial hsp65. Immunology 1995; 86: 519-24.
64. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat. Med. 1996; 2: 888-92.
65. Verbon A, Hartskeerl RA, Schuitema A, Kolk AH, Young DB, Lathigra R. The 14 000-molecular-weight antigen of Mycobacterium tuberculosis is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. J. Bacteriol. 1992; 174: 1352-9.
66. Wu QL, Kong D, Lam K, Husson RN. A mycobacterial extracytoplasmic function sigma factor involved in survival following stress. J. Bacteriol. 1997; 179: 2922-9.
67. Parish CR, Liew FY. Immune response to chemically modified flagellin. 3: Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J. Exp. Med. 1972; 135: 298-311.
68. Bretscher PA. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Immunol. Today 1992; 13: 342-5.
69. Audibert FM, Lise LD. Adjuvants: Current status, clinical perspectives and future prospects. Immunol. Today 1993; 14: 281-4.
70. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune response to tuberculosis sub-unit vaccines. Infect. Immun. 1997; 65: 623-9.
71. Snippe H, Belder M, Willers JM. Dimethyl diotadecyl ammonium bromide as adjuvant for delayed hypersensitivity in mice. Immunology 1977; 33: 931-6.
72. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II: Effect on delayedtype hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum. Bordetella pertussis, muramyl dipeptide and saponin. Clin. Exp. Immunol. 1980; 39: 435-41.
73. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I: Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin. Exp. Immunol. 1980; 39: 426-34.
74. Carozzi S, Salit M, Cantaluppi A et al. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J. Clin. Microbiol. 1989; 27: 1748-53.
75. Salkowski CA, Detore GR, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect. Immun. 1997; 65: 3239-17.
76. Newman MJ, Wu JY, Coughlin RT et al. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates. AIDS Res. Hum. Retroviruses 1992; 8: 1413-18.
77. Wu JY, Gardner BH, Murphy CI et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 1992; 148: 1519-25.
78. Baldwin SL, D'Souza C, Orme IM. Cytokine enhancement of vaccination against tuberculosis. Abstract: 96th General Meeting of the American Society for Microbiology 19-23 May, 1996.
79. Rimmelzwaan GF, Osterhaus ADME. A novel generation ofviral vaccines based on the ISCOM matrix. In. Powell MF, Newman MJ (eds). Vaccine design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995; 543-54.
80. Gregoriadis G. Immunological adjuvants: A role for liposomes. Immunol. Today 1990; 11: 89-97.
81. Baumgart KW, McKenzie KR, Radford AJ, Ramshaw I, Britton WJ. Immunogenicity and protection studies with recombinant mycobacteria and vaccinia vectors coexpressing the 18-kilodalton protein of Mycobacterium leprae. Infect. Immun. 1996; 64: 2274-81.
82. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9.
83. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 1997; 158: 2278-84.